SCHEMBL2177652

SCHEMBL2177652

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)c4ccc(-c5ccccc5)cc4)cn3)cc2C1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.47
PTPN2 P17706 1/20 0.47
KCNQ3 O43525 1/20 0.44
KCNQ2 O43526 1/20 0.44
KCNH2 Q12809 1/20 0.43
MCHR1 Q99705 1/20 0.43
DGAT1 O75907 6/20 0.42
PTPN6 P29350 1/20 0.42
PTPN11 Q06124 1/20 0.42
ITGB3 P05106 2/20 0.42
ITGA2B P08514 2/20 0.42
ITGA2 P17301 2/20 0.42
SDCBP O00560 1/20 0.42
SDC2 P34741 1/20 0.42
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.41
WNT3A P56704 1/20 0.40
MAP3K5 Q99683 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13718837 1.00 PTPN1 (0.47) PTPN1PTPN2KCNQ3KCNQ2KCNH2
SCHEMBL2176996 0.92 DGAT1 (0.42) PTPN1PTPN2DGAT1ITGB3ITGA2B
SCHEMBL2181152 0.92 DGAT1 (0.42) PTPN1PTPN2DGAT1ITGB3ITGA2B
SCHEMBL2178609 0.92 DGAT1 (0.43) PTPN1PTPN2DGAT1PTPN6PTPN11
SCHEMBL2178734 0.92 DGAT1 (0.43) PTPN1PTPN2DGAT1PTPN6PTPN11
SCHEMBL2178118 0.89 LMNA (0.48) PTPN1MCHR1ITGB3ITGA2BITGA2
SCHEMBL13719015 0.89 LMNA (0.48) PTPN1MCHR1ITGB3ITGA2BITGA2
SCHEMBL2180113 0.89 LMNA (0.48) PTPN1MCHR1ITGB3ITGA2BITGA2
SCHEMBL2181050 0.88 PTPN2 (0.40) PTPN1PTPN2DGAT1SDCBPSDC2
SCHEMBL2180263 0.88 PTPN2 (0.40) PTPN1PTPN2DGAT1SDCBPSDC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT PTPN1 2065/4885PTPN2 2343/4885KCNQ3 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.